Undervalued and under the radarZenabis is a better company in many ways than many of the Canadian cannabis leaders. Cronos is being sued by it's investors, Zenabis is not.
Cronos revenue in 2019 was C$24 million, Zenabis's was C$72 million
Cronos price to sales is 91.34, Zenabis is .38
Cronos stock price is $6.23, Zenabis .05 cents
Cronos has over a billion dollars in the bank, Zenabis has $16 million in cash.
Zenabis is poised to overtake Cronos in revenue and profitability this year.
Zenabis stock should be $6.23 a share and Cronos stock should be $1.60 but that's not the world we live in.
We could do this same exercise with
Sundial
Aurora
Organagram
Tilray
Hexo
Supreme Cannabis
Vivo
WeedMD
Indiva
etc, etc, etc
Zenabis is arguably a better positioned and a better run company than any of the above companies and although Indiva is a masterpiece of marketing as is Canopy, Zenabis stock will go up as soon as they turn in significantly good earnings reports over the next two or three quarters. It has to because they are a better company, operationally right now than all but the top two industry leaders, Canopy and Aphria. Remember when Citi Bank was $1.00 a share in 2008 and shareholders couldn't lose because the United States government was backstoping bank failures( after Lehman Brothers that is), this is sort of like that only not quite as obvious to as many people. Zenabis has to produce impressive results with their earnings, if they do, you're gonna wish you bought a lot more at .05 cents a share. The only reason Zenabis is a good buy is because it's .05 cents a share, if it was $6.23 a share, we wouldn't be having this conversation. The companies assets are over $300 million dollars with a market cap of $17 million, state of the art growing facilities, large capacity, high quality production operations with an expanding global presence. Give me a break.......05 cents a share is nonsense and time will prove it.